According to a Bloomberg report, Clario, a clinical trial technology solution provider, has confidentially filed for an initial public offering with the US Securities and Exchange Commission and is targeting a valuation of more than USD 10 billion. The report states that the company is working with underwriters JPMorgan Chase, Morgan Stanley, Jefferies Financial, and UBS Group AG.
While no final decisions have been made and deliberations are underway, one source in the report suggested that the company might consider a listing in 2025.
Analyst QuickTake: As of June 2024, Clario has provided solutions for use in 26,000+ clinical trials across 100 countries, and has contributed to 800+ drug approvals. According to Bloomberg sources, the company is estimated to generate an annual revenue of USD 1.1 billion and an EBITDA of ~USD 400 million. While the company’s performance metrics could help support its aggressive initial valuation, a public filing with the SEC will need to be submitted to proceed with the listing.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.